Eledon Pharmaceuticals (ELDN) Cash from Operations (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Cash from Operations data on file, last reported at 22612000.0 in Q1 2026.

• Quarterly Cash from Operations fell 40.8% year-over-year to 22612000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 68893000.0 (down 26.2% YoY) and the FY2025 annual result came in at 62341000.0, down 31.88% from the prior year.
• Cash from Operations eased to 22612000.0 in Q1 2026, from 14091000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 4571000.0 in Q3 2022 to a low of 22612000.0 in Q1 2026.
• A 5-year average of 11775000.0 and a median of 9924000.0 in 2023 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations jumped 35.56% — and 2023, when it plunged 168.02%.
• Tracing ELDN's Cash from Operations over 5 years: stood at 9480000.0 in 2022, then rose by 3.68% to 9131000.0 in 2023, then plunged by 107.94% to 18987000.0 in 2024, then grew by 25.79% to 14091000.0 in 2025, then tumbled by 60.47% to 22612000.0 in 2026.
• The last three Cash from Operations figures came in at 22612000.0 (Q1 2026), 14091000.0 (Q4 2025), and 14477000.0 (Q3 2025), per Business Quant data.